Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
-
Published:2022-08-08
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Renia Laurent, Goh Yun Shan, Rouers AngelineORCID, Le Bert NinaORCID, Chia Wan NiORCID, Chavatte Jean-MarcORCID, Fong Siew‐Wai, Chang Zi Wei, Zhuo Nicole ZiyiORCID, Tay Matthew ZiruiORCID, Chan Yi-Hao, Tan Chee Wah, Yeo Nicholas Kim‐WahORCID, Amrun Siti Naqiah, Huang Yuling, Wong Joel Xu En, Hor Pei Xiang, Loh Chiew Yee, Wang BeiORCID, Ngoh Eve Zi XianORCID, Salleh Siti Nazihah MohdORCID, Carissimo GuillaumeORCID, Dowla Samanzer, Lim Alicia Jieling, Zhang Jinyan, Lim Joey Ming Er, Wang Cheng-I.ORCID, Ding Ying, Pada Surinder, Sun Louisa Jin, Somani Jyoti, Lee Eng SingORCID, Ong Desmond Luan Seng, Ruesta Anthony Torres, Neo Vanessa, Chen Wendy Yehui, Goh Estelle Yi Wei, Ong Alice Soh Meoy, Chua Adeline Chiew Yen, Nguee Samantha Yee Teng, Tan Yong Jie, Tang Weiyi, Leo Yee‐SinORCID, MacAry Paul A., Lin Raymond Tzer PinORCID, Wang Lin-FaORCID, Ren Ee Chee, Lye David C., Bertoletti Antonio, Young Barnaby EdwardORCID, Ng Lisa F. P.ORCID,
Abstract
AbstractUnderstanding the impact of age on vaccinations is essential for the design and delivery of vaccines against SARS-CoV-2. Here, we present findings from a comprehensive analysis of multiple compartments of the memory immune response in 312 individuals vaccinated with the BNT162b2 SARS-CoV-2 mRNA vaccine. Two vaccine doses induce high antibody and T cell responses in most individuals. However, antibody recognition of the Spike protein of the Delta and Omicron variants is less efficient than that of the ancestral Wuhan strain. Age-stratified analyses identify a group of low antibody responders where individuals ≥60 years are overrepresented. Waning of the antibody and cellular responses is observed in 30% of the vaccinees after 6 months. However, age does not influence the waning of these responses. Taken together, while individuals ≥60 years old take longer to acquire vaccine-induced immunity, they develop more sustained acquired immunity at 6 months post-vaccination. A third dose strongly boosts the low antibody responses in the older individuals against the ancestral Wuhan strain, Delta and Omicron variants.
Funder
Agency for Science, Technology and Research MOH | National Medical Research Council A*STAR | Singapore Institute of Manufacturing Technology
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference149 articles.
1. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). 2. Tenforde, M. W. et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 326, 2043–2054 (2020). 3. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021). 4. Dagan, N. et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021). 5. Muhsen, K, et al. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab918 (2021).
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|